Showing 1251-1260 of 1478 results for "".
- With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realmhttps://practicaldermatology.com/news/with-lifecell-acquisition-allergan-enters-regenerative-medicine-realm/2458341/Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products ALLODERM® and STRATTICETM tissue matrices commonly use
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Novan: Significant Improvement of Genital Warts with SB206https://practicaldermatology.com/news/novan-significant-improvement-of-genital-warts-with-sb206/2458355/Top-line results from Novan Inc.’s Phase 2 clinical trial with SB206 for the treatment of genital warts caused by human papillomavirus, or HPV show statistically significant benefits, the company reports. The highest dose tested, SB206 12%, demonstrated a st
- ASDS Honors Awarded and New Board Members Electedhttps://practicaldermatology.com/news/asds-honors-and-new-board-members/2458362/Four members of the American Society for Dermatologic Surgery (ASDS) recently were recognized with the President’s Award for their extraordinary contributions to the Society or the specialty as a whole, and the ASDS awarded Jeanean D. Carruthers, MD, of Vancouver, British Columbia, Canada,
- Adriane M. Brown Joins Allergan's Board of Directorshttps://practicaldermatology.com/news/adriane-m-brown-joins-allergans-board-of-directors/2458375/Adriane M. Brown is joining Allergan’s board of directors effective February 2017. Ms. Brown is currently President and Chief Operating Officer of Intellectual Ventures LLC, a private global invention company focused on providing access to valua
- Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantageshttps://practicaldermatology.com/news/two-new-studies-suggest-bpx-01-topical-minocycline-may-hold-advantages/2458376/Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne vulgaris. The research was at the Skin Disease Edu
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails.
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based